Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | IM |
had shingles twice- one severe case and a subsequent mild case; Severe itching around injection site; This non-serious case was reported by a other health professional and described the occurrence of injection site itching in a 81-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix (intramuscular). On 17-MAR-2026, an unknown time after receiving Shingrix, the patient experienced injection site itching (Verbatim: Severe itching around injection site). On an unknown date, the patient experienced shingles (Verbatim: had shingles twice- one severe case and a subsequent mild case). On 18-MAR-2026, the outcome of the injection site itching was unknown (duration 1 day). The outcome of the shingles was not reported. It was unknown if the reporter considered the injection site itching and shingles to be related to Shingrix. It was unknown if the company considered the injection site itching and shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 18-MAR-2026 The patient had severe itching at around injection site. The patient also had shingles twice one severe case and a subsequent mild case. The batch number was not provided and a request for this information has been made.